Tumour-agnostic drugs in paediatric cancers.
| dc.contributor.author | Chisholm, JC | |
| dc.contributor.author | Carceller, F | |
| dc.contributor.author | Marshall, LV | |
| dc.date.accessioned | 2021-06-22T14:47:56Z | |
| dc.date.available | 2021-12-22T14:47:56Z | |
| dc.identifier.citation | British journal of cancer, 2020, 122 (10), pp. 1425 - 1427 | |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4647 | |
| dc.identifier.eissn | 1532-1827 | |
| dc.identifier.doi | 10.1038/s41416-020-0770-5 | |
| dc.description.abstract | The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 1425 - 1427 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Pyrazoles | |
| dc.subject | Pyrimidines | |
| dc.subject | Oncogene Proteins, Fusion | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Pharmaceutical Preparations | |
| dc.subject | Protein Kinase Inhibitors | |
| dc.subject | Drug Approval | |
| dc.subject | Pediatrics | |
| dc.subject | Adult | |
| dc.subject | Child | |
| dc.title | Tumour-agnostic drugs in paediatric cancers. | |
| dc.type | Other | |
| dcterms.dateAccepted | 2020-03-01 | |
| rioxxterms.version | VoR | |
| rioxxterms.versionofrecord | 10.1038/s41416-020-0770-5 | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
| rioxxterms.type | Other | |
| dc.relation.isPartOf | British journal of cancer | |
| pubs.issue | 10 | |
| pubs.notes | 6 months | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 122 | |
| pubs.embargo.terms | 6 months | |
| pubs.embargo.date | 2021-12-22T14:47:56Z | |
| icr.researchteam | Sarcoma Clinical Trials in children and young people | |
| icr.researchteam | Sarcoma Clinical Trials in children and young people | en_US |
| dc.contributor.icrauthor | Chisholm, Julia |
Files in this item
This item appears in the following collection(s)
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0